ArticleThe American journal of case reports2025
HIV-Negative African American Man with Gastrointestinal Kaposi Sarcoma Associated with Adalimumab Treatment for Cardiac Sarcoidosis: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Adalimumab is a humanized therapeutic monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-a). Kaposi sarcoma is a rare complication associated with adalimumab treatment. It is a cancer with an indolent course and is highly responsive to chemotherapy agents. This report describes the case of a 65-year-old HIV-negative man with gastrointestinal Kaposi sarcoma associated with adalimumab treatment for cardiac sarcoidosis. CASE REPORT A 65-year-old man with cardiac sarcoidosis on adalimumab presented with gastrointestinal bleeding. Endoscopic evaluation revealed Kaposi sarcoma involving the stomach and colon, confirmed by histopathology showing spindle cell proliferation with vascularity and human herpesvirus-8 positivity. HIV testing was negative. Adalimumab was discontinued, and he was treated with paclitaxel. He improved, and the lesions were resolved with treatment as demonstrated in repeat endoscopy. The patient was moved to active surveillance. CONCLUSIONS The endoscopic and clinical presentations of gastrointestinal Kaposi sarcoma are highly variable. In most cases, definitive diagnosis requires endoscopic biopsy and histopathology. Multiple and deep endoscopic biopsies are crucial to avoid false-negative results. Maintaining a high index of suspicion of Kaposi sarcoma in those on immunosuppressants like adalimumab is vital for the timely diagnosis and treatment of this potentially fatal condition. Such patients are usually responsive to withdrawal of the immunosuppressive agent and/or chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.